Anonymous ID: 75b768 May 6, 2019, 10:30 a.m. No.6429220   🗄️.is 🔗kun   >>9283 >>9380

From past bread notables:

>>6427831

WHAT COUNTRY IS THE GENE STRAIN FROM in the NY patients?

Regarding Candida Auris outbreak in NY that Chuck Schumer wants funding for…..seems to be associated with OTHER COUNTRIES, so IMMIGRATION may be the reason we have it all.

The problem could have been avoided if we did not import foreigners???

According to studies:The phylogenetics of C. auris suggest distinct genotypes exist in different geographical regions with substantial genomic diversity.[12] A variety of sequence-based analytical methods have been used to support this finding. These countries:

The genome isolates originating from other countries as problem being studied other countries, they are finding: Pakistan, India, South Africa, Venezuela, Japan, South Asia (India and Pakistan), South Africa, Venezuela, and Japan , United Kingdom, India, Japan, South Africa, South Korea, and Venezuela, Israel, Asia, South Africa, and Kuwait.

 

 

And, it seems the Wikipedia page is being cited in many new articles has been edited often in April prior to the relase of the news.

 

https://en.wikipedia.org/w/index.php?title=Candida_auris&action=history

 

Schumer: “We’re here to say, now more than ever, with something as deadly as Candida auris, an ounce of prevention is worth a pound of cure,” Schumer said. “The CDC has the power to declare Candida auris the superbug an emergency and money would flow to New York.”

More than half of the 613 confirmed U.S. cases have been in New York. Illinois has had 156 cases, and New Jersey has had 106.

 

Here is just a piece from Wikipedia:

 

History:

C. auris was first described after it was isolated from the ear canal of a 70-year-old Japanese woman at the Tokyo Metropolitan Geriatric Hospital in Japan.[1] It was isolated based on its ability to grow in the presence of the fungicide micafungin, an echinocandin class fungicide.[1] Phenotypic, chemotaxonomic and phylogenetic analyses established C. auris as a new strain of the genus Candida.[1][16]

 

The first three cases of disease-causing C. auris were reported from South Korea in 2011.[17] Two isolates had been obtained during a 2009 study and a third was discovered in a stored sample from 1996.[17] All three cases had persistent fungemia, i.e. bloodstream infection, and two of the patients subsequently died due to complications.[17] Notably, the isolates initially were misidentified as Candida haemulonii and Rhodotorula glutinis using standard methods, until sequence analysis correctly identified them as C. auris.[17] These first cases emphasize the importance of accurate species identification and timely application of the correct antifungal for the effective treatment of candidiasis with C. auris.[17]

 

During 2009–2011, 12 C. auris isolates were obtained from patients at two hospitals in Delhi, India.[18] The same genotype was found in distinct settings: intensive care, surgical, medical, oncologic, neonatal, and pediatric wards, which were mutually exclusive with respect to health care personnel.[18] Most had persistent candidemia and a high mortality rate was observed.[18] All isolates were of the same clonal strain, however, and were only identified positively by DNA sequence analysis.[18] As previously, the strain was misidentified with established diagnostic laboratory tests.[18] The Indian researchers wrote in 2013 that C. auris was much more prevalent than published reports indicate since most diagnostic laboratories do not use sequence-based methods for strain identification.[18]

 

The fungus spread to other continents and eventually, a multi-drug-resistant strain was discovered in Southeast Asian countries in early 2016.[19]

 

The first report of a C. auris outbreak in Europe was an October 2016 in Royal Brompton Hospital, a London cardio-thoracic hospital.[14] In April 2017, CDC director Anne Schuchat named it a "catastrophic threat".[20] As of May 2017 the CDC had reported 77 cases in the United States on its website. Of these, 69 were from samples collected in New York and New Jersey.[21]

 

By February 28, 2019, cases of people having contracted C. auris had risen to 587, with 309 reported in New York, 104 in New Jersey and 144 in Illinois, according to the CDC.[3][22]

 

Since it was first observed in the United Kingdom, it has spread to more than 20 NHS Trust hospitals and infected 200 people.[23]

 

As of February 2019, the CDC has documented cases of C. auris from the following countries: Australia, Austria, Belgium, Canada, China, Colombia, France, Germany, India, Iran, Israel, Japan, Kenya, Kuwait, Malaysia, the Netherlands, Norway, Oman, Pakistan, Panama, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Switzerland, Taiwan, the United Arab Emirates, the United Kingdom, the United States, and Venezuela.[22]

 

https://en.wikipedia.org/wiki/Candida_auris

Anonymous ID: 75b768 May 6, 2019, 10:37 a.m. No.6429283   🗄️.is 🔗kun

>>6429220

PREVIOUS ONE YEAR in a hospital in another country is a big clue…….UMMM……..think how OUR American Hospitals are overrun with illegals!!!! Ya think it spreads in NY>>>>>>>>Dumbass Schumer and DEms and Libs STARTED this shit! by allowing the flow of Illegal immigration and then allowing them to overrun hospitals……now Americans in Hospitals are getting it like wildfire!:

 

Surveillance for clinical cases

CDC recommends that all yeast isolates obtained from a normally sterile site (e.g., bloodstream, cerebrospinal fluid) be identified to the species level so that appropriate initial treatment can be administered based on the typical, species-specific susceptibility patterns.

 

C. auris has been identified from many body sites including bloodstream, urine, respiratory tract, biliary fluid, wounds, and external ear canal. Approximately half of clinical cases in the United States have been in the bloodstream and the remainder have been found in non-invasive body sites. Many clinical laboratories do not typically determine the species of isolates from non-sterile sites since presence of Candida in these sites may represent colonization rather than infection and would not require treatment. However, C. auris is important to identify even from a non-sterile body site because presence of C. auris in any body site can represent wider colonization, posing a risk for transmission and requiring implementation of infection control precautions.

 

When Candida is isolated from non-sterile sites, species-level identification should be considered in certain circumstances, including:

 

When clinically indicated in the care of a patient.

When a case of C. auris infection or colonization has been detected in a facility or unit, in order to detect additional patients colonized. Species identification when Candida is found in non-sterile sites can be implemented for at least one month until no evidence exists of C. auris transmission.

When a patient has had an overnight stay in a healthcare facility outside the United States in the previous one year, especially if in a country with documented C. auris transmission. Colonization for longer than a year has been identified among some C. auris patients; therefore hospitals might also consider determining the species for Candida isolated from patients with more remote exposure to healthcare abroad.

All laboratories, especially laboratories serving healthcare facilities where cases of C. auris have been detected should do the following:

 

Review past microbiology records (as far back as 2015, if possible) to identify cases of confirmed or suspected C. auris (see When to suspect C. auris infections).

Conduct prospective surveillance to identify and report C. auris cases in the future.

 

https://www.cdc.gov/fungal/candida-auris/c-auris-surveillance.html

Anonymous ID: 75b768 May 6, 2019, 10:45 a.m. No.6429380   🗄️.is 🔗kun

>>6429220

NOTICE the states and then think immigration rates:

 

Most C. auris cases in the United States have been detected in the New York City area, New Jersey, and the Chicago area. Strains of C. auris in the United States have been linked to other parts of the world. U.S. C. auris cases are a result of inadvertent introduction into the United States from a patient who recently received healthcare in a country where C. auris has been reported or a result of local spread after such an introduction.

 

Tracking Candida auris

April 30, 2019: Case Count Updated as of March 31, 2019

 

On This Page

U.S. Map

World Map

Candida auris is an emerging fungus that presents a serious global health threat. C. auris causes severe illness in hospitalized patients in several countries, including the United States. Patients can remain colonized with C. auris for a long time and C. auris can persist on surfaces in healthcare environments. This can result in spread of C. auris between patients in healthcare facilities.

 

U.S. Map: Clinical cases of Candida auris reported by U.S. states, as of March 31, 2019

Current map of the number of c. auris clinical cases in the United States

Cases reported prior to 2019 are categorized by the state where the specimen was collected. Cases reported in 2019 are categorized by the patient’s state of residence to reflect the standards of the Nationally Notifiable Disease Surveillance System. Most probable cases were identified when laboratories with current cases of C. auris reviewed past microbiology records for C. auris. Isolates were not available for confirmation. Early detection of C. auris is essential for containing its spread in healthcare facilities.

 

Clinical cases of Candida auris reported by U.S. states, as of March 31, 2019